SV2A and epilepsy: The aim of present study was therefore to verify the hypothesis that chronic LEV treatment induces changes in the expression of SV proteins other than SV2A, in line with the emerging notion that presynaptic proteins are potential therapeutic targets for epilepsy and other neurological diseases (Li and Kavalali, 2017).